Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26914884 | 0.91 | PTPN1 (0.35) | MEN1KMT2APTPN1HDAC8GPR119 | |
| SCHEMBL26914862 | 0.89 | MEN1 (0.34) | MEN1KMT2APTPN1HDAC8GPR119 | |
| SCHEMBL26914886 | 0.81 | PTPN1 (0.34) | MEN1KMT2APTPN1HDAC8GPR119 | |
| SCHEMBL26914831 | 0.78 | MEN1 (0.35) | MEN1KMT2APTPN1HDAC8 | |
| SCHEMBL26914858 | 0.75 | PTPN1 (0.41) | MEN1KMT2APTPN1HDAC8 | |
| SCHEMBL26914901 | 0.73 | PTPN1 (0.40) | MEN1KMT2APTPN1HDAC8 | |
| SCHEMBL26914906 | 0.72 | MEN1 (0.33) | MEN1KMT2APTPN1HDAC8GPR119 | |
| SCHEMBL26914863 | 0.71 | ABHD6 (0.35) | MEN1KMT2APTPN1HDAC8 | |
| SCHEMBL24602711 | 0.71 | MEN1 (0.41) | MEN1KMT2APTPN1HDAC8 | |
| SCHEMBL31621568 | 0.71 | MEN1 (0.41) | MEN1KMT2APTPN1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4289850-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289850-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-116848122-A | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-10-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | F2, PLG, PLAT | MEN1 726/4885KMT2A 2898/4885PTPN1 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.